A Retrospective Study of Long Acting Risperidone Use to Support Treatment Adherence in Youth with Conduct Disorder

키워드

참고문헌 (52)

1. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-5" (2013), American Psychiatric Association
2. Costello EJ, "Prevalence and development of psychiatric disorders in childhood and adolescence", Arch Gen Psychiatry, 60, pp.837~844 (2003)
3. Rey J, "Lewis's child and adolescent psychiatry: A comprehensive textbook", pp.454~467 (2007), Lippincott Williams & Wilkins
4. Steiner H, "Practice parameters for the assessment and treatment of children and adolescents with conduct disorder", J Am Acad Child Adolesc Psychiatry, 36(10 Suppl), pp.122S~139S (1997)
5. Sawyer MG, "The mental health of young people in Australia : key findings from the child and adolescent component of the national survey of mental health and well-being", Aust N Z J Psychiatry, 35, pp.806~814 (2001)
6. Ercan ES, "Risperidone in the treatment of conduct disorder in preschool children without intellectual disability", Child Adolesc Psychiatry Ment Health, 5, pp.10~ (2011)
7. Fergusson DM, "Show me the child at seven : the consequences of conduct problems in childhood for psychosocial functioning in adulthood", J Child Psychol Psychiatry, 46, pp.837~849 (2005)
8. Moffitt T, "Developmental psychopathology", pp.570~598 (2006), John Wiley & Sons
9. Odgers CL, "Female and male antisocial trajectories : from childhood origins to adult outcomes", Dev Psychopathol, 20, pp.673~716 (2008)
10. Erskine HE, "The global burden of conduct disorder and attention-deficit", hyperactivity disorder in 2010, 2014, pp.55, 328~336
11. Kazdin AE, "Parent management training: evidence, outcomes, and issues", J Am Acad Child Adolesc Psychiatry, 36, pp.1349~1356 (1997)
12. Kazdin AE, "Parent management training: treatment for oppositional, aggressive, and antisocial behavior in children and adolescents" (2005), Oxford University Press
13. Kim BN, "The clinical use of risperidone in child & adolescent psychiatry", Clin Psyhcopharmacol Neurosci, 1(Suppl), pp.178~187 (2003)
14. Gurnani T, "Pharmacotherapy of aggression in child and adolescent psychiatric disorders", J Child Adolesc Psychopharmacol, 26, pp.65~73 (2016)
15. Findling RL, "An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder", J Child Adolesc Psychopharmacol, 19, pp.431~439 (2009)
16. Masi G, "Olanzapine treatment in adolescents with severe conduct disorder", Eur Psychiatry, 21, pp.51~57 (2006)
17. Connor DF, "Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder", J Child Adolesc Psychopharmacol, 18, pp.140~156 (2008)
18. Crystal S, "Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges", Health Aff (Millwood), 28, pp.w770~w781 (2009)
19. Turgay A, "Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs", Pediatrics, 110, pp.e34~ (2002)
20. Findling RL, "Longterm, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ", Am J Psychiatry, 161, pp.677~684 (2004)
21. Ipser J, "Systematic review of pharmacotherapy of disruptive behavior disorders in children and adolescents", Psychopharmacology (Berl), 191, pp.127~140 (2007)
22. Pliszka SR, "The Texas Children's Medication Algorithm Project : revision of the algorithm for pharmacotherapy of attention-deficit", hyperactivity disorder, 2006, pp.45, 642~657
23. Aman MG, "What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit", hyperactivity disorder?, 2014, pp.53, 47~60.e1
24. Gadow KD, "Severely aggressive children receiving stimulant medication versus stimulant and risperidone : 12-month follow-up of the TOSCA trial", J Am Acad Child Adolesc Psychiatry, 55, pp.469~478 (2016)
25. "Prescribing information" (2015)[URL]
26. Gerlach M, "Psychiatric drugs in children and adolescents: Basic pharmacology and practical applications", pp.157~218 (2014), Springer-Verlag
27. Pringsheim T, "The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 2: antipsychotics and traditional mood stabilizers", Can J Psychiatry, 60, pp.52~61 (2015)
28. Breen R, "Noncompliance with medication for psychiatric disorders", CNS Drugs, 9, pp.457~471 (1998)
29. Adler LD, "Review of medication adherence in children and adults with ADHD", Postgrad Med, 122, pp.184~191 (2010)
30. Thiruchelvam D, "Moderators and mediators of long-term adherence to stimulant treatment in children with ADHD", J Am Acad Child Adolesc Psychiatry, 40, pp.922~928 (2001)
31. Chacko A, "Improving medication adherence in chronic pediatric health conditions : a focus on ADHD in youth", Curr Pharm Des, 16, pp.2416~2423 (2010)
32. Nosé M, "Clinical interventions for treatment non-adherence in psychosis : meta-analysis", Br J Psychiatry, 183, pp.197~206 (2003)
33. Vieta E, "A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone", World J Biol Psychiatry, 9, pp.219~224 (2008)
34. Fu-I L, "Use of risperidone long-acting injection to support treatment adherence and mood stabilization in pediatric bipolar patients : a case series", J Clin Psychiatry, 70, pp.604~606 (2009)
35. Tutkunkardaş MD, "Long acting risperidone in an adolescent with conduct disorder : a case report", Psychopharmacol Bull, 44, pp.69~72 (2011)
36. Boarati MA, "Six-month open-label follow-up of risperidone long-acting injection use in pediatric bipolar disorder", Prim Care Companion CNS Disord, 15 (2013)
37. Sevcan Karakoc Demirkaya, "Long-acting Injectable Risperidone Use in an 11-Years-Old Bipolar Child", Noro Psikiyatri Arsivi, 53(4), pp.361~363 (2016), AVES Publishing Co.[DOI]
38. Ruan L, "Efficacy and safety of long-acting risperidone on early onset schizophrenia in adolescent patients", African J Pharmacy Pharmacol, 4, pp.184~192 (2010)
39. Yuan-Hwa Chou, "A Systemic Review and Experts’ Consensus for Long-acting Injectable Antipsychotics in Bipolar Disorder", Clinical Psychopharmacology and Neuroscience, 13(2), pp.121~128 (2015), 대한정신약물학회
40. Hidehiro Umehara, "Successful Treatment of Anorexia Nervosa in a 10-year-old Boy with Risperidone Long-acting Injection", Clinical Psychopharmacology and Neuroscience, 12(1), pp.65~66 (2014), 대한정신약물학회
41. Pierre JM, "Extrapyramidal symptoms with atypical antipsychotics:incidence, prevention and management", Drug Saf, 28, pp.191~208 (2005)
42. Kaufman J, "Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version(K-SADS-PL) : initial reliability and validity data", J Am Acad Child Adolesc Psychiatry, 36, pp.980~988 (1997)
43. Gökler B, "Reliability and Validity of Schedule for Affective Disorders and Schizophrenia for School Age Children-Present and Lifetime version-Turkish version(K-SADSPL-T)", Turk J Child Adolesc Ment Health, 11, pp.109~116 (2004)
44. American Psychiatric Association, "Diagnostic criteria from DSM-IV-TR" (2000), American Psychiatric Association
45. Busner J, "The clinical global impressions scale : applying a research tool in clinical practice", Psychiatry(Edgmont), 4, pp.28~37 (2007)
46. Emsley R, "Oral versus injectable antipsychotic treatment in early psychosis : post hoc comparison of two studies", Clin Ther, 30, pp.2378~2386 (2008)
47. Nevels RM, "Psychopharmacology of aggression in children and adolescents with primary neuropsychiatric disorders : a review of current and potentially promising treatment options", Exp Clin Psychopharmacol, 18, pp.184~201 (2010)
48. D'Onofrio BM, "A quasi-experimental analysis of the association between family income and offspring conduct problems", J Abnorm Child Psychol, 37, pp.415~429 (2009)
49. Murray J, "Very early predictors of conduct problems and crime : results from a national cohort study", J Child Psychol Psychiatry, 51, pp.1198~1207 (2010)
50. Farmer CA, "Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit", hyperactivity disorder, 2015, pp.25, 213~224
51. Sacchetti E, "Long-acting injection antipsychotic medications in the management of schizophrenia", Evidence-based Psychiatr Care, 1, pp.27~36 (2015)
52. Arango C, "Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients", J Am Acad Child Adolesc Psychiatry, 53, pp.1179~1190 (2014)

관련 논문AI추천